CTIS2023-503322-39-00招募中1 期
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1 - CSET2022/3545
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Any histologically and genetically confirmed Ewing sarcoma of bone or soft tissue, or round cell sarcomas which are ‘Ewing’s-like’ but negative for EWSR1 gene rearrangement, Subject must be able to swallow and retain oral medication., Written informed consent from the patient and/or the parent/legal guardian, according to local, regional or national regulation prior to any study specific procedures., Patients must be affiliated to a social security system or beneficiary of the same, as per local regulatory requirements (France only), Metastatic disease, Age =2 years and <50 years (from second birthday to 49 years 364 days), Patient assessed as medically fit to receive the Ewing sarcoma standard multimodal treatment and regorafenib, including: -Absolute Neutrophil Count (ANC) = 0.75x109/L, platelets = 75x109/L. -Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) = 5×ULN -Bilirubin = 2×ULN -Creatinine < 2x ULN or creatinine clearance >60 ml/min/1.73 m2 -International normalized ratio (INR)/ Partial thromboplastin time (PTT) INR and PTT = 1.5 x ULN INR & PTT = 1.5xULN, Adequate cardiac function as evidenced by left ventricular ejection fraction (LVEF) =50%) at baseline, as determined by echocardiography, Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as: a BP <95th percentile for sex, age, and height at screening (as per National Heart Lung and Blood Institute [NHLBI] guidelines) and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1. Patients >18 years old should have BP = 150/90 mm Hg., No prior treatment for Ewing sarcoma other than surgery, Negative pregnancy test for female patients of childbearing potential within 7 days prior to study registration, Patient agrees to use highly effective contraception during therapy and for 12 months after last trial treatment (females) or 6 months after last trial treatment (males), where applicable
排除标准
- •Localized tumor or metastatic disease to lung/pleura only., Major surgical procedure or significant traumatic injury within 28 days before starting study treatment, Non-healing wound, ulcer or bone facture., Uncontrolled systemic or local infection requiring systemic tratement, Interstitial lung disease with ongoing signs and symptoms., Known prior history of HBV, HCV, HIV, Any other medical or other condition that, in the opinion of the investigator(s), would preclude the subject’s participation in this clinical study, Contra-indication to the Ewing sarcoma standard multimodal treatment, Pregnant or breastfeeding women or intending to become pregnant during the study., Follow-up not possible due to social, geographic or psychological reasons, Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of oral drugs, A clinically significant ECG abnormality, including a marked prolonged QTcF interval (eg, a repeated demonstration of a QTcF interval >480 msec) Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality, unstable angina, active coronary artery disease and myocardial infarction within 6 months before randomization.) Uncontrolled hypertension (systolic pressure >150 mm Hg or diastolic pressure > 90 mm Hg on repeated measurement) despite optimal medical management, Previous arterial or venous thromboembolisms Grade = 3 per CTCAE v5.0, Hypersensitivity to any active substance or to any excipients, Radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation
研究者
相似试验
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60
进行中（未招募）
1 期
Study of Regorafenib drug for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF gen mutation previously treated with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) plus bevacizumabmetastatic colorectal cancerMedDRA version: 16.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2014-000703-26-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
进行中（未招募）
1 期
Regorafenib as a single agent for treatment of patients with metastatic colorectal cancer (MCRC) who are not candidates for polychemotherapyEUCTR2013-000236-94-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
招募中
1 期
A Phase Ib/II study of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent gastric/gastroesophageal junction/esophageal adenocarcinomaunresectable advanced/recurrent gastric/gastroesophageal junction/esophageal adenocarcinomaJPRN-jRCT2031220089Kawazoe Akihito36
尚未招募
不适用
First-line reogorafenib-nivolumab combination for advanced hepatocellular carcinomaNeoplasmsKCT0004867Asan Medical Center42